Pacific Software Inc. (PFSF) has acquired Dermatrix, a patented first-in-class cosmeceutical asset from Dreamaderm Inc. Dermatrix is the fruition of over $6 million and two decades of research by Dr. Malcolm A. Leissring. It leverages a novel mechanism that preserves insulin in the skin to boost natural collagen production, making it a versatile solution for various dermatological applications. In addition to being ideal for skin care and wound healing, Dermatrix also maximizes the body’s natural processes by blocking insulin-degrading enzyme (IDE), thereby maintaining vital skin health and repair peptides. This acquisition marks the Regents of the University of California as an equity stakeholder in PFSF. Dermatrix had gained significant attention, being showcased at competitive start-up and industry events such as the Golden Passport Demo Day and the Aesthetics Technology Forum (ATF). The CEO of PFSF, Harrysen Mittler, anticipates leveraging capital markets to accelerate the commercialization of Dermatrix. Dr. Leissring, who will now serve as president of PFSF, emphasizes the significant potential of Dermatrix in the booming cosmetics and skin care industry. The Safe Harbor Statement appended to the release highlights the forward-looking nature of statements about PFSF’s strategies and potential risks involved.

Pharmaceuticals and Biotechnology, Healthcare Equipment and Services, Technology,California, United States